Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 22, 2000

View Archived Issues

MDS Nordion to manufacture Altropane diagnostic agent

Lynx Therapeutics enters partnership to identify diabetes-associated SNPs

Dendreon describes therapeutic cancer vaccine technology

NIH offers V1 knockout mice for S. pneumoniae vaccine screening

Peptide vaccines available for licensing from NIH

cDNA clones of tick-borne flavivirus available for licensing from NIH

Suplatast tosilate improves asthma symptoms in a double-blind trial

Malaria incidence and resistance controlled by artesunate-mefloquine treatment

Research links development of type 1 diabetes with inflammation

Mechanism of resistance to ABL tyrosine kinase inhibitor STI-571 explored

Potent, selective human A2B adenosine receptor antagonists reported

Orally active dual NK1/NK2 antagonist synthesized by Schering-Plough

Selective ICAM-1 and E-selectin inhibitors on human endothelial cells explored

Wyeth-Ayerst recommends that certain lots of Norplant not be implanted

Psoriasis therapy proceeds to clinical trials

Interneuron enrolls first patients in phase I/II study of PRO-2000 Gel

Syntheses and SAR presented for DuPont Pharmaceuticals' CRF receptor antagonists

Orphan Medical's Antizol sNDA accepted for filing

FDA approves Santen's levofloxacin eyedrops

Inex's Onco TCS given fast track status

New series of PARP inhibitors claimed by Guilford

Elan and Biogen establish Antegren collaboration agreement

Novel compounds useful for neurological disorders claimed by AstraZeneca

Seven key sessions and symposia from XXII ESC Congress available to Daily Essentials readers

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...